Thyroxine suppressive therapy for benign goiter

Thyroxine suppressive therapy for benign goiter
Thyroxine suppressive therapy for benign goiter

The mean patient age was 39.6 years. There were three patients below 20 years. In comparison, treatment of endemic goiter with iodine also lead to a reduction of hypertrophy, but as demonstrated in rats, also to a reduction of hyperplasia.

1 The prevalence of thyroid nodules varies considerably depending on a variety of factors that include iodine intake within a given population, age, sex, diet, therapeutic and environmental radiation exposure. There is age related increase in nodularity and volume of thyroid gland.

Thyroxine suppression at a dose of 50100 g daily was given in 22 of the 29 Gr).

Lack of thyroxine causes

Thyroid hormone suppressive therapy. One study showed that T4 therapy for nontoxic goiter reduced thyroid. on radioiodine therapy of benign nontoxic.

Twenty (70) patients were between 21 and 50 years and six patients were above 50 years of age. All three male patients were above 40 years of age, whereas females were present in all age groups, from 11 years to above 50 years.

Thyroid hormone suppressive therapy for thyroid nodules and benign goiter See more about Thyroid and Therapy.

Is total thyroidectomy the surgical procedure of choice for benign multinodular goiter?. and thyroxine treatment of. suppressive therapy of.

Table 135.1. Thyrotoxicosis: Thyroid Morphology and Etiological Features a. In contrast to hyperthyroidism, the hypothyroid patient s signs and symptoms are.

In 13 of the 29 patients (45 the duration of nodule was 1 year Table 3 and Figure 2. The FNAC finding in the 29 patients was as follows: colloid goiter - 24, colloid goiter with cystic degeneration - 1 and thyroid cyst - 4 Table 4.

Keywords: Benign, diagnosis, thyroid nodule, thyroxine suppression. How to cite this article: Mitra S, Jha M, Gandhi K M. Does thyroxine suppression therapy help to rationalize surgery in benign euthyroid nodules?.

Thyroxine suppressive therapy for benign goiter. E-mail: moc. [email protected] Copyright Indian Journal of Nuclear Medicine This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The disease duration was 3 years in two (28) of the seven patients. Weight loss and insomnia were the most common symptoms. One patient had thyroid ophthalmopathy. In all seven patients, the thyroid technetium scan showed a raised total uptake, ranging from 10.4 to 24.0 (normal range of uptake ).

Three (43) patients continued to be toxic after 18 months of Carbimazole therapy. Two of these received radioiodine ablation and one underwent subtotal thyroidectomy. One patient relapsed postradioiodine therapy and subsequently underwent subtotal thyroidectomy.

Comments closed